225Ac-ABD147 not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A delta-like ligand 3 (DLL3)-targeting antibody fragment conjugated with a linker-chelator that effectively coordinates Ac-225”In the company’s words, NCT06736418 on ClinicalTrials.gov
- Tested for
- Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
- Main trialPhase 1
- “The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung following platinum-based chemotherapy. An initial group of patients will also be given an experimental imaging agent called 111In-ABD147 to help understand where ABD147 goes in the body. The goal of Phase 1b is to gather additional safety and efficacy data on 225Ac-ABD147 to determine the best dose and to understand how…”In the company’s words, NCT06736418 on ClinicalTrials.gov
Other drugs for Large Cell Neuroendocrine Carcinoma of the Lung
- PembrolizumabMerck & Co. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- ZG006Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Aug 2026 | Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026